Phase 1 Study of an Antigenically Central Influenza A/H5 mRNA-LNP Vaccine in Healthy Adults (H-57317)
Description
Content
º£½ÇÉçÇø’s Vaccine Research Center is enrolling healthy adult volunteers for a clinical research study evaluating an investigational mRNA vaccine designed to protect against the H5N1 influenza (avian flu) virus.
The purpose of the study is to assess the safety, tolerability, and immune response generated by the investigational vaccine.
Key Details
- Study Duration: Approximately 7 months
- Number of Visits: Approximately 7 study visits
- Study Location: º£½ÇÉçÇø, Vaccine Research Center, Houston, Texas
- Compensation: Up to $625 for time and travel
- ClinicalTrials.gov listing: Pending (NCT number forthcoming)
Eligibility Criteria
- Adults aged 18 to 49 years
- In good general health
- No history of severe allergic reactions to vaccines
- Not currently pregnant or breastfeeding
- Additional eligibility criteria will be reviewed by study staff at screening
How to Participate
If you are interested in participating or would like more information, please contact our study team:
Complete our .
Or Contact by Phone: 713-798-4912.
Contact
Phone 1: 713–798–4912
IRB: H-57317
Status:
Active
Created:
